

Special Issue

Exploring the Interplay between Endothelial Cells and Immune Cells in the Pathogenesis of Metabolic Diseases

Message from the Guest Editors

The aim of this Special Issue is to provide a platform for communication and discussion in the field of pharmacology and the techniques currently applied to target metabolic syndromes, with a particular focus on the discovery of innovative drugs that target the vascular endothelium and immune cell interaction. We eagerly look forward to receiving submissions that advance our knowledge in this exciting area of research. We encourage the submission of papers that attend to a wide array of topics, including but not limited to, the following: the impact of remodeling vasculature on drug delivery efficacy, the use of extracellular vesicle-based therapy, the drug targeting of radiotherapy-induced damage, the application of chemotherapy and immunotherapy, the drug targeting of metabolic changes in the metabolic/ tumor microenvironment, and the mechanism of action of innovative drugs. Both basic and clinical research contributions that address these topics are very welcome.

Guest Editors

Dr. Kenneth Chat Pan Cheung

Chinese Medicine - Teaching and Research Division, Hong Kong Baptist University, Hong Kong

Dr. Rodrigo A. Loiola

Blood-Brain Barrier Laboratory (LBHE), UR 2465, University of Artois, F-62300 Lens, France

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/171646

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).